Abstract:OBJECTIVE:To screen potential pan-cancer biomarkers based on The Cancer Genome Atlas (TCGA) database, and to provide help for the diagnosis and prognosis assessment of a variety of cancers. METHODS:"GDC Data Transfer Tool" and "GDCRNATools" packages were used to obtain TCGA database. After data sorting, a total of 13 cancers were selected for further analysis. False disco-very rate (FDR) < 0.05 and fold change (FC) >1.5 were used as the differential expression criteria to screen genes and miRNAs that were up- or down-regulated in all the 13 cancers. In the receiver operating characteristic curve (ROC curve), the area under the curve (AUC), the best cut-off value and the corresponding sensitivity and specificity were used to reflect diagnostic significance. The Kaplan-Meier method was used to calculate the survival probability and then the log-rank test was performed. Hazard ratio (HR) was calculated to reflect prognostic evaluation significance. DAVID tool were used to perform GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis for differentially expressed genes. STRING and TargetScan tools were used to analyze the regulatory network of differentially expressed genes and miRNAs. RESULTS:A total of 48 genes and 2 miRNAs were differentially expressed in all the 13 cancers. Among them, 25 genes were up-regulated, 23 genes and 2 miRNAs were down-regulated. Most differentially expressed genes and miRNAs had good ability to distinguish between the cases and controls, with AUC, sensitivity and specificity up to 0.8-0.9. Survival analysis results show that differentially expressed genes and miRNAs were significantly associated with patient survival in a variety of cancers. Most up-regulated genes were risk factors for patient survival (HR>1), while most down-regulated genes were protective factors for patient survival (0 < HR < 1). The enrichment analysis of GO and KEGG showed that the differentially expressed genes were mostly enriched in biological events related to cell proliferation. In the regulatory network analysis, a total of 13 differentially expressed genes and 2 differentially expressed miRNAs had regulatory and interaction relationships. CONCLUSION:The 48 genes and 2 miRNAs that were differentially expressed in 13 cancers may serve as potential pan-cancer biomarkers, providing help for the diagnosis and prognosis evaluation of a variety of cancers, and providing clues for the development of broad-spectrum tumor therapeutic targets.

Identification of Pan-Cancer Biomarkers Based on the Gene Expression Profiles of Cancer Cell Lines

Using feature selection and Bayesian network identify cancer subtypes based on proteomic data

Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis

A Comprehensive Genomic Pan-Cancer Classification Using the Cancer Genome Atlas Gene Expression Data.

Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data

Combining Gene Essentiality with Feature Selection Method to Explore Multi-Cancer Biomarkers

[Exploratory Screening of Potential Pan-Cancer Biomarkers Based on the Cancer Genome Atlas Database].

Identification and Integrate Analysis of Key Biomarkers for Diagnosis and Prognosis of Non-Small Cell Lung Cancer Based on Bioinformatics Analysis

Identifying Cancer Biomarkers from High-Throughput RNA Sequencing Data by Machine Learning

Investigating Multi-Cancer Biomarkers And Their Cross-Predictability In The Expression Profiles Of Multiple Cancer Types

Pan-cancer Transcriptome Analysis Reveals a Gene Expression Signature for the Identification of Tumor Tissue Origin.

A Common Gene Expression Signature Analysis Method for Multiple Types of Cancer

Functional and Embedding Feature Analysis for Pan-Cancer Classification

Robust Biomarker Discovery for Hepatocellular Carcinoma from High-Throughput Data by Multiple Feature Selection Methods

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types

Correlation of gene expression profiles to identify pancreatic cancer cell lines that best model primary human tumors

Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection

Discovery of Pan-Cancer Related Genes Via Integrative Network Analysis.

Multi-cancer molecular signatures and their interrelationships

Identifying and Analyzing Different Cancer Subtypes Using RNA-seq Data of Blood Platelets.